Cross-Sector entity

Dimensional Fund Advisors LP

Company
5

Of the tracked stories, 1 of 2 also mention AstraZeneca Plc, the most common co-covered peer. The 49-day window averages about 0.3 stories each week. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category.

2 verified stories tracked

Last mentioned: Aug 15, 2026

RSS updates
Share

Entity pulse

Recent coverage · Dimensional Fund Advisors LP

↑
2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Dimensional Fund Advisors LP

Of the tracked stories, 1 of 2 also mention AstraZeneca Plc, the most common co-covered peer. The 49-day window averages about 0.3 stories each week. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average. This profile follows 2 Cross-Sector stories mentioning Dimensional Fund Advisors LP across the period from June 28, 2026 to August 15, 2026.

Stories tracked
2
Per week
0.3
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Dimensional Fund Advisors LP. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Dimensional Fund Advisors LP 2

Finance earnings Neutral 5

Smith-Midland Posts $0.26 EPS, $23.36M Revenue; Shares Rise 1.7%

Smith-Midland's latest quarterly results show a profitable small-cap with an almost 20% return on equity and very low leverage, even as the stock trades about 35% below its 52-week high. The $0.26 EPS and $23.36 million revenue figure, combined with rising institutional holdings, make it a watch item for value-oriented small-cap investors. However, the stock remains below its 50-day and 200-day moving averages, keeping the technical picture cautious.

2 sources

Source: MarketBeat · themarketsdaily.com

Healthcare market trends Neutral 5

AstraZeneca Draws $3.8M+ Institutional Share Accumulation Across 6 Major Funds

Six major institutional investors have collectively added over 3.8 million AstraZeneca shares across recent quarters, signaling strong professional confidence in the company's diversified healthcare portfolio spanning oncology, cardiovascular, respiratory, and rare disease treatments. The sustained buying pattern highlights institutional conviction in AstraZeneca's ability to deliver innovative therapies that address critical unmet medical needs.

2 sources

Source: Ticker Report · Watch List News